Clinical trialEPhase 1Recruiting
Lidocaine Infusion in Pancreatic Cancer
Lidocaine Infusion in Pancreatic Cancer: Translational Studies in a Preclinical Model And Human Subjects
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 8 November 2018
- Expected end
- 1 January 2028
- Enrollment
- 46 participants
- Sites
- 1
- Primary outcomes
- Specimen outcome measure.; Specimen outcome measure.; Specimen outcome measure.; Upregulation or Downregulation of Gene Expression.
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.
Detailed description public domain (ClinicalTrials.gov)
The primary objective of this study is to determine the effect of IV lidocaine infusion on various enzymatic activities and associated pathways in isolated CTCs as well as the number of CTCs during the perioperative period in patients undergoing robotic pancreatectomy for pancreatic cancer. It is expected that by downregulating the pathways by lidocaine might affect the enzymatic activity in those CTCs as well as the number of CTCs in the circulation. A prospective randomized controlled double blinded trial design will be used for the proposed study. Patients undergoing robotic pancreatectomy for pancreatic cancer will be randomized (ratio 1:1) into two groups: one group will receive a 24-h normal saline infusion and the second group will receive a 24-h lidocaine infusion. Blood samples will be collected in different times perioperatively in order to evaluate the objectives of the study.